{"url_path":"/sec/indp/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023362-index.html","accession_number":"0001493152-26-023362","cik":"0001857044","ticker":"INDP","issuer_name":"Indaptus Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023362-index.html","primary_entity_key":"0001857044","primary_entity_name":"Indaptus Therapeutics, Inc."},"word_count":190,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors**\n\n \n\nExcept\nas set forth below in this Item 1A and the Risk Factors included in our previous filings made with the SEC, there have been no material\nchanges to our risk factors from those disclosed in “Part I. Item 1A. Risk Factors” in the Form 10-K filed with the SEC on\nMarch 17, 2026.\n\n \n\n**Recent\nchanges in executive management may create uncertainties during the Company’s transition period**\n\n \n\nAs previously disclosed, on March 23, 2026, certain\nsecurities previously held by Mr. David E. Lazar were transferred to third-party purchasers pursuant to the terms of the applicable Securities\nPurchase Agreement. Following these transactions, changes to the Company’s executive management occurred, including the resignation\nof Messrs. Lazar and Jeffrey Meckler from their executive officer positions.\n\n \n\nDuring\nthis transition period, the Company may experience operational, organizational and governance-related adjustments as the current management\nteam continues to evaluate corporate priorities, internal processes and capital allocation initiatives. In addition, there may be further\nchanges to the Company’s executive management team in the future. Any such developments could create uncertainties that may adversely\naffect the Company’s business, financial condition and results of operations."}